Shutterstock
If you have the choice between making a major purchase on a credit card or a personal loan, your first choice should be neither.
Your first choice – if you will not be able to pay back the purchase by the end of the month – should be cash. If you do not have the cash, then you should consider skipping the purchase until you have saved enough money.
Now, that may be easier said than done.
There may be important life milestones, medical necessities and other purchases that necessitate financing, given your personal financial circumstances and financial life goals.
While credit cards have many benefits and offer all types of rewards (cash back, travel and more), they are not always the best option – particularly for longer-term financing needs.
For these major purchases and life milestones – if sufficient cash is not readily available – a personal loan may be a less expensive option.
Top 10 Medical Stocks To Own For 2018: ONEOK Partners L.P.(OKS)
Advisors’ Opinion:
- [By Matthew DiLallo]
Energy infrastructure companies ONEOK (NYSE:OKE) and TransCanada (NYSE:TRP) are both emerging from the energy market downturn as stronger entities. Each made smart acquisitions, with TransCanada buying U.S. gas pipeline company Columbia Pipeline Group, while ONEOK is in the process of gobbling up its MLP,ONEOK Partners (NYSE:OKS). While these deals enhanced the growth profiles of both companies, TransCanada still stands out as the better buy for long-term income investors. Here’s why.
- [By Garrett Cook]
Citi maintains Buy ratings on Targa Resources (NYSE: TRGP), ONEOK (NYSE: OKE) and Oneok Partners (NYSE: OKS) citing the companies stories around natural gas liquids (NGLs).
Top 10 Medical Stocks To Own For 2018: Chesapeake Energy Corporation(CHK)
Advisors’ Opinion:
- [By Paul Ausick]
Chesapeake Energy Corp. (NYSE: CHK) traded up about 3.4% at $3.94 in a 52-week range of $3.41 to $8.20.
EOG Resources Inc. (NYSE: EOG) traded up about 0.9% at $102.50. The 52-week range is $81.99 to $109.37.
- [By WWW.KIPLINGER.COM]
When it comes to energy stocks to watch, Chesapeake Energy Corporation (CHK) has to be on the top of the list.
This past quarter, CHK continued on its transition plans to reduce its heavy debt load, remake its portfolio of assets and live to see another day. And it seemed at first, CHK was doing just that. The natural gas fracker, however, was hit by some pretty bad news at the end of the quarter.
- [By Johanna Bennett]
Yet again, Chesapeake Energy (CHK) has tumbled to the bottom of the S&P 500, delivering the biggest declines of the day despite a rise in natural gas prices.
Chesapeake Energy dropped 4.2%, or 26 cents to $5.89, while the S&P 500 declined 0.68% to 2,328.95. Front Month Nymex natural gas for May delivery rose 1.35% to $3.230 per million British thermal units.
Last month, Stifel Nicolaus analyst Karl Chalabala kicked off coverage of the natural-gas and oil-exploration company with a buy rating, saying the stock would give investors exposure to a bullish demand cycle. At $10, his price target suggested, at that time, that the stock could double over the next 12 months.
Chesapeake has fallen more than 16% since the start of 2017
- [By Paul Ausick]
Chesapeake Energy Corp. (NYSE: CHK) posted a new 52-week low of $3.59 on Monday, down about 5.3% from Friday’s closing price of $3.79. The stock’s 52-week high is $8.20. Volume totaled around 36 million shares, about 1 million more than the daily average. The company acknowledged that its oil & gas production would be constrained as long as Harvey continues to keep refineries and terminals closed.
- [By Matthew DiLallo]
The high-end represents a robust growth rate for a company of its size. For perspective, the nation’s second-largest gas producer,Chesapeake Energy (NYSE:CHK), sees its output rising 5% to 15% annually through 2020. Meanwhile, smaller rival Antero Resources expects to grow 20% to 25% this year, while delivering 20% to 22% annual growth from 2018 to 2020. However, that is off a lower production base of roughly 657 billions of cubic feet equivalent compared to 870 billions of cubic feet equivalent for Southwestern.
- [By Kumar Abhishek]
Shares ofChesapeake Energy Corporation(NYSE:CHK) have been in a downtrend over the past three months, declining 25% in this period. In a bearish move,Chesapeake Energy Corporation’s 50-day and 200-day SMA’s formed a death cross afew days ago. A death cross is a strong bearish signal. However, the stock continued to climb up. Chesapeake Energy Corporation technical chart, the stock has broken out above the 20-day SMA which had provided strong resistance in the past. A breakout above the 20-day SMA resistance in spite of death cross suggests astrong bullish trend. The stock is now forming a double bottom pattern. The double bottom is a bullish trend reversal pattern, which indicates a medium term reversal in the trend. The double bottom patternwill be complete when the stock hits the previous high.
Top 10 Medical Stocks To Own For 2018: Accenture plc.(ACN)
Advisors’ Opinion:
- [By Steve Symington]
The stock market was mostly flat today ahead of a key House vote on the passage of the Republicans’ healthcare bill, which was delayed until Friday after GOP lawmakers failed to gather the necessary support. TheDow Jones Industrial Averagelost just 5 points, or 0.02%, while other broader market indexes saw similar small declines. But several individual stocks saw much more severe drops, including Zillow Group (NASDAQ:Z) (NASDAQ:ZG), Proofpoint (NASDAQ:PFPT), and Accenture (NYSE:ACN). Read on to see what drove these unusual moves.
- [By Laurie Kulikowski]
With a dividend payout ratio of 44% and dividend yield of 2%, we consider Accenture our favorite income oriented security, recognizing valuation is near peak multiples. Fundamentally, we believe its mix of business should result in above-average revenue growth, and mix allows for modest margin expansion (rare in IT Services), that should result in steady and attractive double-digit total returns to shareholders.
- [By Laurie Kulikowski]
The company, on the basis of net income growth from the same quarter one year ago, has significantly underperformed compared to the IT Services industry average, but is greater than that of the S&P 500. The net income increased by 5.2% when compared to the same quarter one year prior, going from $701.02 million to $737.63 million.
- [By Lisa Levin]
In trading on Thursday, industrial shares fell by 0.08 percent. Meanwhile, top losers in the sector included Accenture Plc (NYSE: ACN), down 4 percent, and Manitex International Inc (NASDAQ: MNTX), down 4 percent.
Top 10 Medical Stocks To Own For 2018: Vermillion, Inc.(VRML)
Advisors’ Opinion:
- [By Alex McGuire]
Here’s a list of the top 10 penny stocks to watch in March, which includes the biggest gainers last month…
Penny StockCurrent Stock PriceFebruary 2017 ReturnZosano Pharma Corp. (Nasdaq: ZSAN)$2.56+123.3%Bellerophon Therapeutics Inc. (Nasdaq: BLPH)$1.25+113.8%Peregrine Pharmaceuticals (Nasdaq: PPHM)$0.59+101.7%Galectin Therapeutics Inc. (Nasdaq: GALT)$1.79+91.9%Bioanalytical Systems Inc. (Nasdaq: BASI)$1.58+90.6%CymaBay Therapeutics Inc. (Nasdaq: CBAY)$3.50+89.8%Vermillion Inc. (Nasdaq: VRML)$2.56+86.3%Naked Brand Group Inc.(Nasdaq:NAKD)$2.16+76%Eyegate Pharmaceuticals Inc. (Nasdaq: EYEG)$2.63+73.9%Benitec Biopharma Ltd. (Nasdaq ADR: BNTC)$2.60+59.9%
The best-performing penny stock – Zosano Pharma Corp. – soared an incredible 123.3% from Feb. 1 to Feb. 28. To put those gains into perspective, that’s more than five times the S&P 500’s 23% climb in the last 12 months.
Top 10 Medical Stocks To Own For 2018: Eagle Bulk Shipping Inc.(EGLE)
Advisors’ Opinion:
- [By Lisa Levin]
Shares of Eagle Bulk Shipping Inc (NASDAQ: EGLE) were down 49 percent to $0.381. Eagle Bulk Shipping announced after Wednesday’s close it has reached an agreement with its lenders and holders of its equity to raise $105 million.
Top 10 Medical Stocks To Own For 2018: Blackrock Global(BOE)
Advisors’ Opinion:
- [By Robert Rapier]
Whiting Petroleum (WLL) is one of Continental’s biggest competitors in the Bakken. Whiting is the second-largest oil producer in North Dakota, averaging 82,500 barrels of oil equivalent (BOE) of production in 2012, across more than 700,000 acres of leased land.
Top 10 Medical Stocks To Own For 2018: Intellipharmaceutics International Inc.(IPCI)
Advisors’ Opinion:
- [By Lisa Levin]
IntelliPharmaCeutics Intl Inc (USA) (NASDAQ: IPCI) shares dropped 45 percent to $1.38 as the company disclosed that a FDA panel voted against approving the company’s NDA for Rexista™ abuse-deterrent oxycodone hydrochloride extended release tablets.
Top 10 Medical Stocks To Own For 2018: Nutraceutical International Corporation(NUTR)
Advisors’ Opinion:
- [By Lisa Levin]
Non-cyclical consumer goods & services sector was the top gainer in the US market on Monday. Top gainers in the sector included Nutraceutical Int'l Corp. (NASDAQ: NUTR), BRF SA (ADR) (NYSE: BRFS), and Chefs' Warehouse Inc (NASDAQ: CHEF).
Top 10 Medical Stocks To Own For 2018: Rubicon Technology, Inc.(RBCN)
Advisors’ Opinion:
- [By Jim Robertson]
On Thursday, our Under the Radar Moversnewsletter suggested shorting small cap LED semiconductor stockRubicon Technology (NASDAQ: RBCN):
Rubicon Technology isn’t going to be a monster-sized winner for us, even if things go perfectly. About the best downside target we could hope for is the $0.60 area, where the stock was launched into an unsustainable uptrend a week ago. But, it’s a high-odds trade we can’t pass up. Yesterday’s doji bar after a big rally was a warning sign that we were transitioning into a net-selling environment. Today’s sharp pullback confirms we’re moving into that bearish mode.
Top 10 Medical Stocks To Own For 2018: Enbridge Inc(ENB)
Advisors’ Opinion:
- [By Jim Robertson]
On Friday, our Under the Radar Moversnewsletter suggested shorting small cap energy transportation and distribution stock Enbridge Inc (NYSE: ENB):
- [By Matthew DiLallo]
Not to be outdone, rival Canadian oil pipeline giant Enbridge (NYSE:ENB) announced a transformational gas-focused deal of its own, agreeing to acquire U.S. pipeline company Spectra Energy (NYSE:SE) for $28 billion. That transaction will catapult Enbridge past TransCanada and create the largest energy infrastructure company in North America. Further, the deal will bolster Enbridge’s near-term capital project backlog to $20 billion, while enhancing its inventory of longer-term investment opportunities to $37 billion. This pipeline supports Enbridge’s view that it can increase its dividend by 10% to 12% annually through 2024.
